Free Trial

AbCellera Biologics (ABCL) Stock Forecast & Price Target

$3.85
0.00 (0.00%)
(As of 05/24/2024 ET)

AbCellera Biologics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 7 Analyst Ratings

Consensus Price Target

$16.17
319.91% Upside
High Forecast$24.00
Average Forecast$16.17
Low Forecast$7.00
TypeCurrent Forecast
5/26/23 to 5/25/24
1 Month Ago
4/26/23 to 4/25/24
3 Months Ago
2/25/23 to 2/25/24
1 Year Ago
5/26/22 to 5/26/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
7 Buy rating(s)
9 Buy rating(s)
8 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$16.17$15.86$15.86$25.57
Forecasted Upside319.91% Upside221.60% Upside221.60% Upside152.66% Upside
Get AbCellera Biologics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter.

ABCL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ABCL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AbCellera Biologics Stock vs. The Competition

TypeAbCellera BiologicsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.70
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside319.91% Upside834.72% Upside9.91% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Forecasts and Stock Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/8/2024KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$8.00 ➝ $7.00+84.70%
2/22/2024Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$9.00+87.11%
2/21/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$21.00 ➝ $17.00+220.15%
11/3/2023Bloom Burton
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Martin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
10/13/2023Piper Sandler Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight$20.00+402.51%
8/4/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$27.00 ➝ $24.00+278.55%
5/5/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$16.00 ➝ $15.00+150.84%
2/28/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
2/22/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$34.00+282.45%
2/22/2023BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$40.00 ➝ $32.00+259.95%
1/6/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$20.00 ➝ $18.00+89.47%
11/16/2022Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$29.00+100.14%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:34 PM ET.

ABCL Frequently Asked Questions

What is AbCellera Biologics's stock forecast and purchase recommendation?

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for AbCellera Biologics is $16.17, with a high forecast of $24.00 and a low forecast of $7.00. The consensus rating for AbCellera Biologics stock is Buy based on the current 7 buy ratings for ABCL. Learn more on ABCL's analyst rating history.

Do Wall Street analysts like AbCellera Biologics more than its competitors?

Analysts like AbCellera Biologics more than other "medical" companies. The consensus rating for AbCellera Biologics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ABCL compares to other companies.

Does AbCellera Biologics's stock price have much upside?

According to analysts, AbCellera Biologics's stock has a predicted upside of 243.85% based on their 12-month stock forecasts.

What analysts cover AbCellera Biologics?

AbCellera Biologics has been rated by research analysts at KeyCorp in the past 90 days.


Stock Forecasts and Research Tools

This page (NASDAQ:ABCL) was last updated on 5/25/2024 by MarketBeat.com Staff

From Our Partners